(NASDAQ: MBX) Mbx Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 56.52%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 101.52%.
Mbx Biosciences's earnings in 2025 is N/A.On average, 8 Wall Street analysts forecast MBX's earnings for 2025 to be -$92,064,087, with the lowest MBX earnings forecast at -$98,922,768, and the highest MBX earnings forecast at -$83,176,547. On average, 8 Wall Street analysts forecast MBX's earnings for 2026 to be -$93,270,707, with the lowest MBX earnings forecast at -$104,818,827, and the highest MBX earnings forecast at -$77,561,253.
In 2027, MBX is forecast to generate -$114,247,843 in earnings, with the lowest earnings forecast at -$128,730,622 and the highest earnings forecast at -$84,229,415.